• Caris Life Sciences Showcases Data on KRAS Mutations in Patients With Non-Small Cell Lung and Pancreatic Cancer at ASCO20 Virtual Scientific Program

    The combination of DNA sequencing and whole transcriptome sequencing provides critical insights that can guide treatment decisions across a range of cancers   IRVING, Texas, May 29, 2020 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, will present results from a study today that characterize KRAS mutations in patients with non-small cell lung cancer (NSCLC). In this study, the molecular profiles of more than 17,000 patients with NSCLC were evaluated using the Caris Molecular Intelligence® platform, … Read More

  • Rutgers Cancer Institute of New Jersey Joins Caris Life Sciences’ Precision Oncology Alliance

    New Jersey’s only NCI-designated Comprehensive Cancer Center becomes the 37th member of Caris’ collaborative network focused on expanding the application of precision medicine in cancer treatment   IRVING, Texas & NEW BRUNSWICK, N.J. May 19, 2020 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that Rutgers Cancer Institute of New Jersey has become the 37th member of its Caris Precision Oncology Alliance™. … Read More

  • Caris Life Sciences to Present Data Spotlighting Clinical Impact of Precision Medicine in ASCO20 Virtual Scientific Program

    Data from 14 studies to highlight role of company’s portfolio of precision medicine technologies in guiding treatment decisions for patients with cancer across tumor types   IRVING, Texas, May 11, 2020 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that the company will present 14 studies as part of the American Society of Clinical Oncology’s ASCO20 Virtual Scientific Program. These presentations will showcase Caris’ industry-leading portfolio of precision medicine technologies and demonstrate how a tailored approach can impact the course of disease for people living with a cancer diagnosis, … Read More

  • Caris Life Sciences Submits Two PMA Applications to the FDA for Whole Exome and Whole Transcriptome Sequencing

    IRVING, Texas, April 28, 2020 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the submission of two Pre-Market Approval (PMA) applications for MI Exome CDx and MI TranscriptomeCDx to the U.S. Food and Drug Administration (FDA). MI ExomeCDx, whole exome sequencing (DNA), and MI Transcriptome CDx, … Read More

  • Caris Life Sciences Launches Whole Exome Sequencing with MI Exome

    The most comprehensive suite of molecular testing in the industry includes a new whole exome sequencing (DNA) assay complementing the Company’s breakthrough whole transcriptome sequencing (RNA) performed on every patient    IRVING, Texas, April 22, 2020 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the launch of MI Exome, a next-generation sequencing-based assay analyzing the whole exome of 22,000 DNA genes. … Read More